Table 3

Prevalence of autoantibodies in patients with SLE, non-IMID controls, rest group, BBD controls and patients with other IMIDs, and prevalence of autoantibodies in patients with SLE with nephritis

Antibody target	Prevalence in SLE n (%)	SLE vs non-IMID controls (p value)	Prevalence rest n (%)	SLE vs rest (p value)	Prevalence BBD controls n (%)	SLE vs BBD controls (p value)	Prevalence IMIDs n (%)	SLE vs IMIDs (p value)	Prevalence in pts with nephritis n (%)	SLE nephritis vs non-nephritis (p value)
dsDNA	199 (41.2)	3.9E-22	26 (5.5)	1.3E-38	4 (1.1)	2.0E-41	42 (12.1)	1.0E-19	76 (47.2)	NS
CpG	194 (40.2)	3.0E-21	42 (8.9)	4.1E-29	26 (7.2)	3.7E-27	55 (15.9)	5.6E-14	77 (47.8)	1.5E-02*
RipP1	161 (33.3)	7.8E-16	55 (11.7)	1.2E-15	18 (5.0)	2.1E-23	49 (14.2)	3.9E-10	61 (37.9)	NS
SmBB	147 (30.4)	9.6E-14	41 (8.7)	2.9E-17	12 (3.3)	2.2E-23	38 (11)	3.3E-11	59 (36.6)	3.6E-02*
Histones	134 (27.7)	6.5E-12	40 (8.5)	1.2E-14	35 (9.7)	9.0E-11	60 (17.3)	4.9E-04	55 (34.2)	2.6E-02*
RipP0	133 (27.5)	8.9E-12	36 (7.6)	7.6E-16	19 (5.3)	8.0E-17	49 (14.2)	4.5E-06	44 (27.3)	NS
Nucleosome	129 (26.7)	3.1E-11	32 (6.8)	2.0E-16	16 (4.4)	2.1E-17	47 (13.6)	5.2E-06	55 (34.2)	8.8E-03*
RipP2	127 (26.3)	5.8E-11	41 (8.7)	9.0E-13	4 (1.1)	1.6E-23	46 (13.3)	5.6E-06	44 (27.3)	NS
Ro60	119 (24.6)	6.5E-10	30 (6.4)	7.0E-7	0 (0)	2.6E-24	53 (15.3)	1.1E-03*	46 (28.6)	NS
CMV	108 (22.4)	1.6E-08	45 (9.5)	6.6E-8	9 (2.5)	1.4E-16	37 (10.7)	1.3E-05	51 (31.7)	5.1E-04
RNPA	94 (19.5)	7.4E-07	43 (9.1)	5.0E-6	14 (3.9)	2.0E-11	56 (16.2)	NS	27 (16.8)	NS
Ro52	89 (18.4)	2.7E-06	27 (5.7)	1.9E-9	1 (0.3)	2.9E-17	50 (14.5)	NS	32 (19.9)	NS
RNP70	77 (15.9)	5.6E-05	24 (5.1)	4.9E-8	7 (1.9)	1.8E-11	37 (10.7)	3.0E-02*	24 (14.9)	NS
SMP	74 (15.3)	1.1E-04	23 (4.9)	9.1E-8	7 (1.9)	6.6E-11	17 (4.9)	2.3E-06	31 (19.3)	NS
LaSSB	71 (14.7)	2.3E-04	19 (4.0)	1.7E-8	0 (0)	2.7E-14	30 (8.7)	8.9E-03*	27 (16.8)	NS
C1q	69 (14.3)	3.7E-04	20 (4.2)	9.3E-8	16 (4.4)	2.5E-06	16 (4.6)	6.1E-06	29 (18.0)	NS
RNPC	69 (14.3)	3.7E-04	22 (4.7)	4.1E-7	18 (5.0)	1.1E-05	30 (8.7)	1.4E-02*	20 (12.4)	NS
H2Bp	60 (12.4)	2.7E-03*	18 (3.8)	1.2E-6	15 (4.2)	3.0E-05	8 (2.3)	1.7E-07	26 (16.1)	NS
C3b	57 (11.8)	5.2E-03*	29 (6.1)	2.2E-3*	19 (5.3)	1.0E-03*	29 (8.4)	NS	22 (13.7)	NS
Ku	51 (10.6)	1.7E-02*	27 (5.7)	6.3E-3*	6 (1.7)	3.5E-07	22 (6.4)	3.5E-02*	17 (10.6)	NS
RA33	50 (10.4)	2.1E-02*	17 (3.6)	4.4E-5	9 (2.5)	9.4E-06	20 (5.8)	2.0E-02*	19 (11.8)	NS
Actinin	50 (10.4)	2.1E-02*	44 (9.3)	NS	22 (6.1)	2.8E-02*	43 (12.4)	NS	15 (9.3)	NS
Cardiolipin	49 (10.1)	2.5E-02*	36 (7.6)	NS	16 (4.4)	2.1E-03*	21 (6.1)	3.7E-02*	15 (9.3)	NS
H2Bpac	44 (9.1)	NS	18 (3.8)	9.0E-4*	16 (4.4)	8.9E-03*	16 (4.6)	1.4E-02*	26 (16.1)	NS
H4p	42 (8.7)	NS	23 (4.8)	1.9E-2*	11 (3.0)	8.2E-04	13 (3.8)	4.8E-03*	16 (9.9)	NS
Pentraxin3	41 (8.5)	NS	35 (7.4)	NS	14 (3.9)	7.3E-03*	14 (4)	1.1E-02*	15 (9.3)	NS
CRP	35 (7.2)	NS	16 (3.4)	8.0E-3*	4 (1.1)	2.6E-05	10 (2.9)	6.3E-03*	15 (9.3)	NS
ASCA	18 (3.7)	NS	19 (4.0)	NS	10 (2.8)	NS	15 (4.3)	NS	13 (8.1)	3.6E-04
Mi2	31 (6.4)	NS	27 (5.7)	NS	14 (3.9)	NS	17 (4.9)	NS	16 (9.9)	2.6E-02*

Only autoantibodies with significant differences between groups are shown, antibodies not shown in this table did not significantly differ between groups. Due to the fixed specificity of 95%, used to determine the cut-offs for all autoantibodies, the prevalence of all autoantibodies in the non-IMID controls is 5% and is therefore not shown in this table. Statistical analysis by χ² test. P values are given (E-05=10⁻⁵).
*No significant difference after Bonferroni correction.
BBD, blood bank donor; IMID, immune-mediated inflammatory disease; NS, not significant.